Key result
Using a larger self-expanding transcatheter heart valve yielded superior hydrodynamic performance, including lower gradients and larger effective orifice areas, when implanted high in a bench model.
Why the study?
The implications of hydrodynamic testing to guide valve-in-valve sizing are poorly understood, beyond sizing based on transcatheter heart valve and surgical valve dimensions.
Does the use of larger self-expanding transcatheter heart valves improve hydrodynamic performance in valve-in-valve procedures compared to smaller valves?
Does the use of larger self-expanding transcatheter heart valves improve hydrodynamic performance in valve-in-valve procedures compared to smaller valves?
In a bench model of valve-in-valve procedures, larger self-expanding transcatheter heart valves demonstrated superior hydrodynamic performance when implanted high compared to smaller valves.
Bench findings should not guide ViV sizing; hypothesis-generating and leaves clinical translation open.
AIMS: The commonly used valve-in-valve (VIV) app recommends sizing based on dimensions of both the transcatheter heart valve (THV) and bioprosthetic surgical valve. The implications of hydrodynamic testing to guide VIV sizing are poorly understood. This bench study assessed the hydrodynamic performance of different sizes of self-expanding supra-annular THVs in three different surgical aortic bioprostheses at different implantation depths. METHODS: A small versus medium ACURATE neo (ACn), and a 26 mm versus 29 mm Evolut R were assessed after VIV implantation in 25 mm Mitroflow, Mosaic, and Magna Ease aortic surgical bioprostheses, at three implantation depths (+2 mm, -2 mm, and -6 mm). RESULTS: The medium-sized ACn had lower gradients compared to the small ACn when the THV was implanted high (+2 mm, or -2 mm). The 29 mm Evolut R had lower gradients compared to a 26 mm Evolut R for all implantation depths, except for a depth of -2 mm in the 25 mm Mitroflow. The medium ACn and 29 mm Evolut R had larger effective orifice areas compared to the small ACn and 26 mm Evolut R, respectively. Both Evolut R sizes had acceptable regurgitant fractions (<15%), while both ACn sizes were above the acceptable performance criteria (>15%), at all implantation depths. CONCLUSIONS: Use of a larger self-expanding THV was associated with superior hydrodynamic performance if the THV was implanted high. Hydrodynamic testing can provide additional information to the VIV app to help guide VIV sizing.
No takes yet. Share an insight, caveat, or question.
Sathananthan et al. (2019) studied Valve-in-valve procedures. Larger self-expanding transcatheter heart valves (medium ACURATE neo, 29 mm Evolut R) vs. Smaller transcatheter heart valves (small ACURATE neo, 26 mm Evolut R) was evaluated on Hydrodynamic performance (gradients, effective orifice area, and regurgitant fraction). Using a larger self-expanding transcatheter heart valve yielded superior hydrodynamic performance, including lower gradients and larger effective orifice areas, when implanted high in a bench model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: